

Linong Ji

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/123395/publications.pdf>

Version: 2024-02-01

341
papers

12,893
citations

50276

46
h-index

31849

101
g-index

350
all docs

350
docs citations

350
times ranked

14809
citing authors

#	ARTICLE	IF	CITATIONS
1	Multicenter Evaluation Study Comparing a New Factory-Calibrated Real-Time Continuous Glucose Monitoring System to Existing Flash Glucose Monitoring System. <i>Journal of Diabetes Science and Technology</i> , 2023, 17, 208-213.	2.2	8
2	A Glycemia Risk Index (GRI) of Hypoglycemia and Hyperglycemia for Continuous Glucose Monitoring Validated by Clinician Ratings. <i>Journal of Diabetes Science and Technology</i> , 2023, 17, 1226-1242.	2.2	69
3	Guideline Development for Medical Device Technology: Issues for Consideration. <i>Journal of Diabetes Science and Technology</i> , 2023, 17, 1698-1710.	2.2	2
4	The effect of education and mobile health management on improvement of blood glucose with type 2 diabetes mellitus. <i>Zeitschrift Fur Gesundheitswissenschaften</i> , 2022, 30, 205-209.	1.6	3
5	Association Between Non-Alcoholic Fatty Liver Disease and Diabetes-Related Microvascular Complications: A Retrospective Cross-Sectional Study of Hospitalized Patients. <i>Endocrine Practice</i> , 2022, 28, 304-309.	2.1	9
6	Association Between Iodine Nutritional Status and Adverse Pregnancy Outcomes in Beijing, China: a Single-Center Cohort Study. <i>Biological Trace Element Research</i> , 2022, 200, 2620-2628.	3.5	6
7	Incidence rates and predictors of microvascular and macrovascular complications in patients with type 2 diabetes: Results from the longitudinal global discover study. <i>American Heart Journal</i> , 2022, 243, 232-239.	2.7	14
8	Safety and tolerability of linagliptin in Asians with type 2 diabetes: a pooled analysis of 4457 patients from 21 randomized, double-blind, placebo-controlled clinical trials. <i>Expert Opinion on Drug Safety</i> , 2022, 21, 425-434.	2.4	2
9	Cardiovascular benefits beyond urinary glucose excretion: <sc>A hypothesis generated from two meta-analyses</sc>. <i>Diabetes, Obesity and Metabolism</i> , 2022, 24, 550-554.	4.4	3
10	Reflections on a successful hybrid type 1 diabetes summer camp in China during the COVID-19 pandemic. <i>Journal of Diabetes</i> , 2022, , .	1.8	0
11	The Effects of Supervised Exercise Training on Weight Control and Other Metabolic Outcomes in Patients With Type 2 Diabetes: A Meta-Analysis. <i>International Journal of Sport Nutrition and Exercise Metabolism</i> , 2022, 32, 186-194.	2.1	4
12	Impact of micro- and macrovascular complications of type 2 diabetes on quality of life: Insights from the DISCOVER prospective cohort study. <i>Endocrinology, Diabetes and Metabolism</i> , 2022, 5, e00321.	2.4	9
13	A Randomized Controlled Clinical Trial of Lifestyle Intervention and Pioglitazone for Normalization of Glucose Status in Chinese with Prediabetes. <i>Journal of Diabetes Research</i> , 2022, 2022, 1-10.	2.3	2
14	Trends and regional differences in glycemic control of patients with type 2 diabetes in China, 2009-2013. <i>Chinese Medical Journal</i> , 2022, 135, 1637-1638.	2.3	1
15	ADA/EASD Precision Medicine in Diabetes Initiative: An International Perspective and Future Vision for Precision Medicine in Diabetes. <i>Diabetes Care</i> , 2022, 45, 261-266.	8.6	53
16	Quality of life in people with type 2 diabetes in the 3 years following initiation of second-line therapy: The DISCOVER study. <i>Diabetes Research and Clinical Practice</i> , 2022, 185, 109218.	2.8	4
17	A variation in SORBS1 is associated with type 2 diabetes and high-density lipoprotein cholesterol in Chinese population. <i>Diabetes/Metabolism Research and Reviews</i> , 2022, 38, e3524.	4.0	3
18	Hereditary renal glycosuria, diabetes and responses to <sc>SGLT2</sc> inhibitor. <i>Journal of Diabetes</i> , 2022, 14, 216-220.	1.8	4

#	ARTICLE	IF	CITATIONS
19	The Association between Non-Alcoholic Fatty Liver Disease (NAFLD) and Advanced Fibrosis with Serological Vitamin B12 Markers: Results from the NHANES 1999–2004. <i>Nutrients</i> , 2022, 14, 1224.	4.1	22
20	GAD65 Antibody Epitopes and Genetic Background in Latent Autoimmune Diabetes in Youth (LADY). <i>Frontiers in Immunology</i> , 2022, 13, 836952.	4.8	5
21	Report from the CVOT Summit 2021: new cardiovascular, renal, and glycemic outcomes. <i>Cardiovascular Diabetology</i> , 2022, 21, 50.	6.8	8
22	Self-Monitoring of Blood Glucose as an Integral Part in the Management of People with Type 2 Diabetes Mellitus. <i>Diabetes Therapy</i> , 2022, 13, 829-846.	2.5	9
23	Factors associated with weight loss in people with overweight or obesity living with type 2 diabetes mellitus: Insights from the global <i>DISCOVER</i> study. <i>Diabetes, Obesity and Metabolism</i> , 2022, 24, 1734-1740.	4.4	0
24	Association Between Indices of Body Composition and Metabolically Unhealthy Phenotype in China: A Cross-Sectional Study. <i>Frontiers in Endocrinology</i> , 2022, 13, .	3.5	5
25	Assessment of ovarian reserve in patients with type 1 diabetes: a systematic review and meta-analysis. <i>Endocrine</i> , 2022, 77, 205-212.	2.3	2
26	Expert consensus on personalized initiation of glucose-lowering therapy in adults with newly diagnosed type 2 diabetes without clinical cardiovascular disease or chronic kidney disease. <i>Journal of Evidence-Based Medicine</i> , 2022, 15, 168-179.	1.8	3
27	The association between the use of sodium glucose cotransporter 2 inhibitor and the risk of diabetic retinopathy and other eye disorders: a systematic review and meta-analysis. <i>Expert Review of Clinical Pharmacology</i> , 2022, 15, 877-886.	3.1	5
28	A multicenter all-inclusive prospective study on the relationship between glycemic control markers and maternal and neonatal outcomes in pregnant women. <i>Journal of Maternal-Fetal and Neonatal Medicine</i> , 2021, 34, 3154-3161.	1.5	4
29	Use of sodium-glucose cotransporter 2 inhibitors in Asian patients with type 2 diabetes and kidney disease: An Asian perspective and expert recommendations. <i>Diabetes, Obesity and Metabolism</i> , 2021, 23, 299-317.	4.4	20
30	Dipeptidyl peptidase 4 inhibitor treatment and the risk of bullous pemphigoid and skin-related adverse events: A systematic review and meta-analysis of randomized controlled trials. <i>Diabetes/Metabolism Research and Reviews</i> , 2021, 37, e3391.	4.0	13
31	Efficacy and safety of once-weekly semaglutide versus once-daily sitagliptin as add-on to metformin in patients with type 2 diabetes in <i>SUSTAIN China</i> : A 30-week, double-blind, phase 3a, randomized trial. <i>Diabetes, Obesity and Metabolism</i> , 2021, 23, 404-414.	4.4	45
32	The impact of ferritin on the disassociation of HbA1c and mean plasma glucose. <i>Journal of Diabetes</i> , 2021, 13, 512-520.	1.8	3
33	Flash glucose monitoring data analysed by detrended fluctuation function on beta cell function and diabetes classification. <i>Diabetes, Obesity and Metabolism</i> , 2021, 23, 774-781.	4.4	3
34	Genetic variants of ABCC8 and phenotypic features in Chinese early onset diabetes. <i>Journal of Diabetes</i> , 2021, 13, 542-553.	1.8	9
35	Impact of age at type 2 diabetes mellitus diagnosis on mortality and vascular complications: systematic review and meta-analyses. <i>Diabetologia</i> , 2021, 64, 275-287.	6.3	140
36	Low-Frequency Genetic Variant in the Hepatic Glucokinase Gene Is Associated With Type 2 Diabetes and Insulin Resistance in Chinese Population. <i>Diabetes</i> , 2021, 70, 809-816.	0.6	3

#	ARTICLE	IF	CITATIONS
37	Association of serum fibroblast growth factor 21 and urinary glucose excretion in hospitalized patients with type 2 diabetes. <i>Journal of Diabetes and Its Complications</i> , 2021, 35, 107750.	2.3	4
38	Phase III, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of teneligliptin monotherapy in Chinese patients with type 2 diabetes mellitus inadequately controlled with diet and exercise. <i>Journal of Diabetes Investigation</i> , 2021, 12, 537-545.	2.4	8
39	Global patterns of comprehensive cardiovascular risk factor control in patients with type 2 diabetes mellitus: Insights from the DISCOVER study. <i>Diabetes, Obesity and Metabolism</i> , 2021, 23, 39-48.	4.4	11
40	Efficacy and safety of teneligliptin added to metformin in Chinese patients with type 2 diabetes mellitus inadequately controlled with metformin: A phase 3, randomized, double-blind, placebo-controlled study. <i>Endocrinology, Diabetes and Metabolism</i> , 2021, 4, e00222.	2.4	6
41	Sex- and age-related trajectories of the adult human gut microbiota shared across populations of different ethnicities. <i>Nature Aging</i> , 2021, 1, 87-100.	11.6	86
42	Type 2 diabetes and heart failure: insights from the global DISCOVER study. <i>ESC Heart Failure</i> , 2021, 8, 1711-1716.	3.1	10
43	Age-stratified association of blood pressure with albuminuria and left ventricular hypertrophy in patients with hypertension and diabetes mellitus. <i>Blood Pressure</i> , 2021, 30, 180-187.	1.5	2
44	A Pragmatic Study of Basal and Mid-Mixture Insulins as Starter Insulins in Chinese Patients With Type 2 Diabetes: Observations From Long-Term, Real-World Experience. <i>Diabetes Therapy</i> , 2021, 12, 931-941.	2.5	0
45	Chinese clinical practice guidelines for perioperative blood glucose management. <i>Diabetes/Metabolism Research and Reviews</i> , 2021, 37, e3439.	4.0	6
46	Sex differences in the prevalence of obesity in 800,000 Chinese adults with type 2 diabetes. <i>Endocrine Connections</i> , 2021, 10, 139-145.	1.9	4
47	Efficacy and safety of PEGylated exenatide injection (PB-119) in treatment-naïve type 2 diabetes mellitus patients: a Phase II randomised, double-blind, parallel, placebo-controlled study. <i>Diabetologia</i> , 2021, 64, 1066-1078.	6.3	2
48	SGLT2 inhibitors and lower limb complications: an updated meta-analysis. <i>Cardiovascular Diabetology</i> , 2021, 20, 91.	6.8	32
49	Generalizability of the Results of Cardiovascular Outcome Trials of Glucagon-Like Peptide 1 Receptor Agonists in Chinese Patients with Type 2 Diabetes Mellitus. <i>Diabetes Therapy</i> , 2021, 12, 1861-1870.	2.5	5
50	Associations between second-line glucose-lowering combination therapies with metformin and HbA1c, body weight, quality of life, hypoglycaemic events and glucose-lowering treatment intensification: The DISCOVER study. <i>Diabetes, Obesity and Metabolism</i> , 2021, 23, 1823-1833.	4.4	7
51	Inappropriate intensification of glucose-lowering treatment in older patients with type 2 diabetes: the global DISCOVER study. <i>BMJ Open Diabetes Research and Care</i> , 2021, 9, e001585.	2.8	4
52	A Guideline-Based Decision Tree Achieves Better Glucose Control with Less Hypoglycemia at 3 Months in Chinese Diabetic Patients. <i>Diabetes Therapy</i> , 2021, 12, 1887-1899.	2.5	1
53	Non-Insulin Antidiabetes Treatment in Type 1 Diabetes Mellitus: A Systematic Review and Meta-Analysis. <i>Diabetes and Metabolism Journal</i> , 2021, 45, 312-325.	4.7	5
54	A case report of pseudohypoadosteronism type II with a homozygous KLHL3 variant accompanied by hyperthyroidism. <i>BMC Endocrine Disorders</i> , 2021, 21, 103.	2.2	4

#	ARTICLE	IF	CITATIONS
55	Prevalence and progression of chronic kidney disease among patients with type 2 diabetes: Insights from the DISCOVER study. <i>Diabetes, Obesity and Metabolism</i> , 2021, 23, 1956-1960.	4.4	8
56	A Two-Stage Study Identifies Two Novel Polymorphisms in PRKAG2 Affecting Metformin Response in Chinese Type 2 Diabetes Patients. <i>Pharmacogenomics and Personalized Medicine</i> , 2021, Volume 14, 745-755.	0.7	3
57	Urinary C-peptide/creatinine ratio: A useful biomarker of insulin resistance and refined classification of type 2 diabetes mellitus. <i>Journal of Diabetes</i> , 2021, 13, 893-904.	1.8	8
58	Effect of empagliflozin on cardiorenal outcomes and mortality according to body mass index: A subgroup analysis of the EMPA-REG OUTCOME trial with a focus on Asia. <i>Diabetes, Obesity and Metabolism</i> , 2021, 23, 1886-1891.	4.4	18
59	Association between dyslipidemia and antihypertensive and antidiabetic treatments in a China multicenter study. <i>Journal of Clinical Hypertension</i> , 2021, 23, 1399-1404.	2.0	5
60	Comparison of insulin glargine 300 U/mL versus glargine 100 U/mL on glycemic control and hypoglycemic events in East Asian patients with type 2 diabetes: A Patient-level meta-analysis of phase 3 studies. <i>Diabetes Research and Clinical Practice</i> , 2021, 176, 108848.	2.8	4
61	NAFLD or MAFLD: Which Has Closer Association With All-Cause and Cause-Specific Mortality? Results From NHANES III. <i>Frontiers in Medicine</i> , 2021, 8, 693507.	2.6	67
62	SGLT2i increased the plasma fasting glucagon level in patients with diabetes: A meta-analysis. <i>European Journal of Pharmacology</i> , 2021, 903, 174145.	3.5	5
63	Effect of Baseline Characteristics on Hypoglycaemia Risk with Insulin Glargine 100 U/mL: Post Hoc Analysis of the BEYOND 7 Study. <i>Diabetes Therapy</i> , 2021, 12, 2359-2369.	2.5	0
64	Towards living guidelines on cardiorenal outcomes in diabetes: A pilot project of the Taskforce of the Guideline Workshop 2020. <i>Diabetes Research and Clinical Practice</i> , 2021, 177, 108870.	2.8	4
65	Early versus late intensification of glucose-lowering therapy in patients with type 2 diabetes: Results from the DISCOVER study. <i>Diabetes Research and Clinical Practice</i> , 2021, 178, 108947.	2.8	3
66	The Biological Disease-Modifying Antirheumatic Drugs and the Risk of Cardiovascular Events: A Systematic Review and Meta-Analysis. <i>Mediators of Inflammation</i> , 2021, 2021, 1-12.	3.0	12
67	What are the factors associated with long-term glycaemic control in patients with type 2 diabetes and elevated glycated haemoglobin ($\geq 7.0\%$) at initiation of second-line therapy? Results from the DISCOVER study. <i>Diabetes, Obesity and Metabolism</i> , 2021, 23, 2336-2343.	4.4	6
68	Characteristics, treatment patterns, and glycemic control of older type 2 diabetes mellitus patients in China. <i>Chinese Medical Journal</i> , 2021, Publish Ahead of Print, 2893-2895.	2.3	0
69	Development and validation of a risk score model for prediction of lower extremity arterial disease in Chinese with type 2 diabetes aged over 50 years. <i>Endocrine Connections</i> , 2021, 10, 1212-1220.	1.9	2
70	Clinical and Genetic Characteristics of ABCC8 Nonneonatal Diabetes Mellitus: A Systematic Review. <i>Journal of Diabetes Research</i> , 2021, 2021, 1-14.	2.3	8
71	Cardiovascular outcomes of antidiabetes medications by race/ethnicity: A systematic review and meta-analysis. <i>Journal of Diabetes and Its Complications</i> , 2021, 35, 107980.	2.3	3
72	IBI362 (LY3305677), a weekly-dose GLP-1 and glucagon receptor dual agonist, in Chinese adults with overweight or obesity: A randomised, placebo-controlled, multiple ascending dose phase 1b study. <i>EClinicalMedicine</i> , 2021, 39, 101088.	7.1	23

#	ARTICLE	IF	CITATIONS
73	Health-related quality of life in patients with type 2 diabetes initiating a second-line glucose-lowering therapy: The DISCOVER study. <i>Diabetes Research and Clinical Practice</i> , 2021, 180, 108974.	2.8	3
74	Early combination versus initial metformin monotherapy in the management of newly diagnosed type 2 diabetes: An East Asian perspective. <i>Diabetes, Obesity and Metabolism</i> , 2021, 23, 3-17.	4.4	16
75	Genetics and Clinical Characteristics of PPAR β Variant-Induced Diabetes in a Chinese Han Population. <i>Frontiers in Endocrinology</i> , 2021, 12, 677130.	3.5	5
76	Cardiovascular risk profile and clinical characteristics of diabetic patients. <i>Chinese Medical Journal</i> , 2021, Publish Ahead of Print, .	2.3	0
77	Cost-Effectiveness of Flash Glucose Monitoring for the Management of Patients with Type 1 and Patients with Type 2 Diabetes in China. <i>Diabetes Therapy</i> , 2021, 12, 3079-3092.	2.5	9
78	Screening strategy for islet autoantibodies in diabetes patients of different ages. <i>Diabetes Technology and Therapeutics</i> , 2021, , .	4.4	5
79	Safety, tolerability, pharmacokinetics, and pharmacodynamics of the glucokinase activator PB-201 and its effects on the glucose excursion profile in drug-naïve Chinese patients with type 2 diabetes: a randomised controlled, crossover, single-centre phase 1 trial. <i>EClinicalMedicine</i> , 2021, 42, 101185.	7.1	5
80	Do East Asians With Normal Glucose Tolerance Have Worse β -Cell Function? A Meta-Analysis of Epidemiological Studies. <i>Frontiers in Endocrinology</i> , 2021, 12, 780557.	3.5	1
81	The Effect of Physical Activity on Glycemic Variability in Patients With Diabetes: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. <i>Frontiers in Endocrinology</i> , 2021, 12, 767152.	3.5	8
82	The Urinary Glucose Excretion by Sodium-Glucose Cotransporter 2 Inhibitor in Patients With Different Levels of Renal Function: A Systematic Review and Meta-Analysis. <i>Frontiers in Endocrinology</i> , 2021, 12, 814074.	3.5	10
83	Association of serum fibroblast growth factor 21 with kidney function in a population-based Chinese cohort. <i>Medicine (United States)</i> , 2021, 100, e28238.	1.0	0
84	Factors Associated with Acute Complications among Individuals with Type 1 Diabetes in China: The 3C Study. <i>Endocrine Research</i> , 2020, 45, 1-8.	1.2	1
85	Evaluation of effectiveness of treatment paradigm for newly diagnosed type 2 diabetes patients in China: A nationwide prospective cohort study. <i>Journal of Diabetes Investigation</i> , 2020, 11, 151-161.	2.4	9
86	The Prevalence of Osteoporosis Tested by Quantitative Computed Tomography in Patients With Different Glucose Tolerances. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2020, 105, 201-209.	3.6	9
87	Efficacy of metformin in preventing progression to diabetes in a Chinese population with impaired glucose regulation: Protocol for a multicentre, open-label, randomized controlled clinical study. <i>Diabetes, Obesity and Metabolism</i> , 2020, 22, 158-166.	4.4	5
88	Early life exposure to 1959-1961 Chinese famine exacerbates association between diabetes and cardiovascular disease. <i>Journal of Diabetes</i> , 2020, 12, 134-141.	1.8	24
89	Albuminuria and other target organ damage in Chinese patients with hypertension and diabetes: A data analysis based on the ATTEND study. <i>Journal of Diabetes and Its Complications</i> , 2020, 34, 107470.	2.3	6
90	Denosumab or romosozumab therapy and risk of cardiovascular events in patients with primary osteoporosis: Systematic review and meta-analysis. <i>Bone</i> , 2020, 130, 115121.	2.9	71

#	ARTICLE	IF	CITATIONS
91	Glycaemic control in patients with type 2 diabetes initiating second-line therapy: Results from the global DISCOVER study programme. <i>Diabetes, Obesity and Metabolism</i> , 2020, 22, 66-78.	4.4	20
92	Linagliptin and cardiorenal outcomes in Asians with type 2 diabetes mellitus and established cardiovascular and/or kidney disease: subgroup analysis of the randomized CARMELINA® trial. <i>Diabetology International</i> , 2020, 11, 129-141.	1.4	17
93	Search for clinical predictors of good glycemic control in patients starting or intensifying oral hypoglycemic pharmacological therapy: A multicenter prospective cohort study. <i>Journal of Diabetes and Its Complications</i> , 2020, 34, 107464.	2.3	4
94	Erythrocytosis and Performance of HbA1c in Detecting Diabetes on an Oxygen-Deficient Plateau: A Population-based Study. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2020, 105, e1612-e1620.	3.6	4
95	Efficacy and safety of insulin glargine 300 U/mL versus insulin glargine 100 U/mL in Asia Pacific insulin-naïve people with type 2 diabetes: The EDITION AP randomized controlled trial. <i>Diabetes, Obesity and Metabolism</i> , 2020, 22, 612-621.	4.4	17
96	Chinese Famine and the diabetes mellitus epidemic. <i>Nature Reviews Endocrinology</i> , 2020, 16, 123-123.	9.6	12
97	Management of Type 2 Diabetes in Developing Countries: Balancing Optimal Glycaemic Control and Outcomes with Affordability and Accessibility to Treatment. <i>Diabetes Therapy</i> , 2020, 11, 15-35.	2.5	39
98	The association between the biological disease-modifying anti-rheumatic drugs and the incidence of diabetes: A systematic review and meta-analysis. <i>Pharmacological Research</i> , 2020, 161, 105216.	7.1	8
99	Age, sex, disease severity, and disease duration difference in placebo response: implications from a meta-analysis of diabetes mellitus. <i>BMC Medicine</i> , 2020, 18, 322.	5.5	5
100	<p>Prevalence of Thyroid Dysfunction in a Chinese Population with Different Glucose Intolerance Status: A Community-Based Cross-Sectional Study</p>. <i>Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy</i> , 2020, Volume 13, 4361-4368.	2.4	11
101	<p>Association Between Abnormal Glycemic Phenotypes and Microvascular Complications of Type 2 Diabetes Mellitus Outpatients in China</p>. <i>Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy</i> , 2020, Volume 13, 4651-4659.	2.4	3
102	Risk prediction model of gestational diabetes mellitus based on nomogram in a Chinese population cohort study. <i>Scientific Reports</i> , 2020, 10, 21223.	3.3	27
103	Insulin glargine/lixisenatide fixed-ratio combination (<scp>iGlarLixi</scp>) compared with premix or addition of meal-time insulin to basal insulin in people with type 2 diabetes: A systematic review and Bayesian network meta-analysis. <i>Diabetes, Obesity and Metabolism</i> , 2020, 22, 2179-2188.	4.4	14
104	Type 1 diabetes induced by immune checkpoint inhibitors. <i>Chinese Medical Journal</i> , 2020, 133, 2595-2598.	2.3	14
105	Metformin discontinuation in patients beginning second-line glucose-lowering therapy: results from the global observational DISCOVER study programme. <i>BMJ Open</i> , 2020, 10, e034613.	1.9	3
106	Relationship between anti-thyroid peroxidase antibody positivity and pregnancy-related and fetal outcomes in Euthyroid women: a single-center cohort study. <i>BMC Pregnancy and Childbirth</i> , 2020, 20, 491.	2.4	26
107	Glycemic Control Following GLP-1 RA or Basal Insulin Initiation in Real-World Practice: A Retrospective, Observational, Longitudinal Cohort Study. <i>Diabetes Therapy</i> , 2020, 11, 2629-2645.	2.5	14
108	Hb broomhill [± 1 or ± 2 114(GH2) proα or β] or αHBA1 or αHBA2β:c.343CαG]: a rare Hb variant found in a diabetic chinese individual. <i>Scandinavian Journal of Clinical and Laboratory Investigation</i> , 2020, 80, 606-609.	1.2	0

#	ARTICLE	IF	CITATIONS
109	Validation of the Swedish Diabetes Re-Grouping Scheme in Adult-Onset Diabetes in China. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2020, 105, e3519-e3528.	3.6	25
110	Prevalence of Albuminuria in Cardiology and Endocrinology Departments and Its Influencing Factors: A Multicenter, Real-World Evidence Study in China. <i>International Journal of Hypertension</i> , 2020, 2020, 1-7.	1.3	1
111	Cover Image, Volume 22, Issue 5. <i>Diabetes, Obesity and Metabolism</i> , 2020, 22, .	4.4	0
112	The Morbidity and Comorbidity of Nonalcoholic Fatty Liver Disease and Different Glucose Intolerance Strata in a Community-Based Chinese Population. <i>Metabolic Syndrome and Related Disorders</i> , 2020, 18, 284-290.	1.3	2
113	Glycemic control and the incidence of neoplasm in patients with type 2 diabetes: a meta-analysis of randomized controlled trials. <i>Endocrine</i> , 2020, 70, 232-242.	2.3	9
114	Response to Denosumab and Romosozumab do not increase the risk of cardiovascular events in patients with primary osteoporosis: A reanalysis of the meta-analysis. <i>Bone</i> , 2020, 134, 115271.	2.9	0
115	Socioeconomic factors associated with hypoglycaemia in patients starting second-line glucose-lowering therapy: The DISCOVER study. <i>Diabetes Research and Clinical Practice</i> , 2020, 165, 108250.	2.8	4
116	Diabetes and COVID-19: Risks, Management, and Learnings From Other National Disasters. <i>Diabetes Care</i> , 2020, 43, 1695-1703.	8.6	147
117	Insulin delivery with a needle-free insulin injector versus a conventional insulin pen in Chinese patients with type 2 diabetes mellitus: A 16-week, multicenter, randomized clinical trial (the FREE) <i>TJ ETQq1 1 0.784314 rgBT5/Overlo</i>		
118	Loss of HNF1 α Function Contributes to Hepatocyte Proliferation and Abnormal Cholesterol Metabolism via Downregulating miR-122: A Novel Mechanism of MODY3. <i>Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy</i> , 2020, Volume 13, 627-639.	2.4	10
119	The Association Between Serum Thyrotropin Within the Reference Range and Metabolic Syndrome in a Community-Based Chinese Population. <i>Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy</i> , 2020, Volume 13, 2001-2011.	2.4	8
120	Serum leptin, resistin, and adiponectin levels in obese and non-obese patients with newly diagnosed type 2 diabetes mellitus. <i>Medicine (United States)</i> , 2020, 99, e19052.	1.0	58
121	Simple-to-use nomogram for evaluating the incident risk of moderate-to-severe LEAD in adults with type 2 diabetes: A cross-sectional study in a Chinese population. <i>Scientific Reports</i> , 2020, 10, 3182.	3.3	7
122	Silent hemoglobin variant during capillary electrophoresis: A case report. <i>Journal of Diabetes Investigation</i> , 2020, 11, 1014-1017.	2.4	2
123	Sex-influenced association of metabolic syndrome with lower extremity arterial disease in type 2 diabetes. <i>Journal of Diabetes and Its Complications</i> , 2020, 34, 107537.	2.3	4
124	Is visceral abdominal fat area a better indicator for hyperglycemic risk? Results from the Pinggu Metabolic Disease Study. <i>Journal of Diabetes Investigation</i> , 2020, 11, 888-895.	2.4	6
125	Blood pressure and glucose control and the prevalence of albuminuria and left ventricular hypertrophy in patients with hypertension and diabetes. <i>Journal of Clinical Hypertension</i> , 2020, 22, 212-220.	2.0	14
126	Higher versus standard starting dose of insulin glargine 100 U/mL in overweight or obese Chinese patients with type 2 diabetes: Results of a multicentre, open-label, randomized controlled trial (BEYOND VII). <i>Diabetes, Obesity and Metabolism</i> , 2020, 22, 838-846.	4.4	7

#	ARTICLE	IF	CITATIONS
127	Patient characteristics and 6-month dose of basal insulin associated with HbA1c achievement <7.0% in Chinese people with type 2 diabetes: results from the Observational Registry of Basal Insulin Treatment (ORBIT). <i>Journal of Diabetes</i> , 2020, 12, 668-676.	1.8	6
128	A pragmatic study of midâ€mixture insulin and basal insulin treatment in patients with type 2 diabetes uncontrolled with oral antihyperglycaemic medications: A lesson from realâ€world experience. <i>Diabetes, Obesity and Metabolism</i> , 2020, 22, 1436-1442.	4.4	5
129	Greater macrovascular and microvascular morbidity from type 2 diabetes in northern compared with southern China: A cross-sectional study. <i>Journal of Diabetes Investigation</i> , 2020, 11, 1285-1294.	2.4	4
130	Factors associated with glycemic control in type 1 diabetes patients in China: A cross-sectional study. <i>Journal of Diabetes Investigation</i> , 2020, 11, 1575-1582.	2.4	11
131	Practical recommendations for the management of diabetes in patients with COVID-19. <i>Lancet Diabetes and Endocrinology</i> , 2020, 8, 546-550.	11.4	680
132	<p>Achieving Effective and Efficient Basal Insulin Optimal Management by Using Mobile Health Application (APP) for Type 2 Diabetes Patients in China<p>. <i>Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy</i> , 2020, Volume 13, 1327-1338.	2.4	8
133	Factors and outcomes associated with discontinuation of basal insulin therapy in patients with type 2 diabetes mellitus. <i>Endocrinology, Diabetes and Metabolism</i> , 2020, 3, e00122.	2.4	4
134	New clinical screening strategy to distinguish HNF1A variant-induced diabetes from young early-onset type 2 diabetes in a Chinese population. <i>BMJ Open Diabetes Research and Care</i> , 2020, 8, e000745.	2.8	7
135	Effect of Hemoglobin A1c Reduction or Weight Reduction on Blood Pressure in Glucagon-Like Peptide-1 Receptor Agonist and Sodium-Glucose Cotransporter-2 Inhibitor Treatment in Type 2 Diabetes Mellitus: A Meta-Analysis. <i>Journal of the American Heart Association</i> , 2020, 9, e015323.	3.7	22
136	Serum Ratio of Free Triiodothyronine to Thyroid-Stimulating Hormone: A Novel Index for Distinguishing Graves' Disease From Autoimmune Thyroiditis. <i>Frontiers in Endocrinology</i> , 2020, 11, 620407.	3.5	2
137	A Deep Reinforcement Learning Approach for Type 2 Diabetes Mellitus Treatment. , 2020, , .		6
138	The Body Weight Alteration and Incidence of Neoplasm in Patients With Type 2 Diabetes: A Meta-Analysis of Randomized Controlled Trials. <i>Frontiers in Endocrinology</i> , 2020, 11, 541699.	3.5	4
139	Use of SGLT-2 Inhibitors in Patients with Type 2 Diabetes Mellitus and Abdominal Obesity: An Asian Perspective and Expert Recommendations. <i>Diabetes and Metabolism Journal</i> , 2020, 44, 11.	4.7	30
140	<p>Treatment Effects of Short-Term Continuous Positive Airway Pressure on Blood Glucose Control in Type 2 Diabetic Patients with Obstructive Sleep Apnea Syndrome<p>. <i>International Journal of General Medicine</i> , 2020, Volume 13, 1567-1573.	1.8	2
141	Factors associated with resistance to complications in long-standing type 1 diabetes in China. <i>Endocrine Connections</i> , 2020, 9, 187-193.	1.9	0
142	Effects of Incretin-based Therapies on Weight-related Indicators among Patients with Type 2 Diabetes: A Network Meta-analysis. <i>Biomedical and Environmental Sciences</i> , 2020, 33, 37-47.	0.2	2
143	Direct medical costs for patients with type 2 diabetes in 16 tertiary hospitals in urban China: A multicenter prospective cohort study. <i>Journal of Diabetes Investigation</i> , 2019, 10, 539-551.	2.4	30
144	Safety and tolerability of empagliflozin in East Asian patients with type 2 diabetes: Pooled analysis of phase III clinical trials. <i>Journal of Diabetes Investigation</i> , 2019, 10, 418-428.	2.4	27

#	ARTICLE	IF	CITATIONS
145	Baseline Triglyceride Level Affected the Efficacy of Vildagliptin in Treating Type 2 Diabetes: A Post Hoc Analysis of the VISION Study. <i>Journal of Diabetes Research</i> , 2019, 2019, 1-5.	2.3	1
146	Serum Albumin, but not Bilirubin, is Associated with Diabetic Chronic Vascular Complications in a Chinese Type 2 Diabetic Population. <i>Scientific Reports</i> , 2019, 9, 12086.	3.3	18
147	Risk of Malignant Neoplasia with Glucagon-Like Peptide-1 Receptor Agonist Treatment in Patients with Type 2 Diabetes: A Meta-Analysis. <i>Journal of Diabetes Research</i> , 2019, 2019, 1-10.	2.3	21
148	A culturally sensitive nurse-led structured education programme in patients with type 2 diabetes. <i>International Journal of Nursing Practice</i> , 2019, 25, e12757.	1.7	8
149	Use of sodium-glucose co-transporter-2 inhibitors in patients with type 2 diabetes mellitus and multiple cardiovascular risk factors: An Asian perspective and expert recommendations. <i>Diabetes, Obesity and Metabolism</i> , 2019, 21, 2354-2367.	4.4	22
150	A nationwide assessment of blood pressure control and the associated factors in Chinese type 2 diabetes mellitus patients. <i>Journal of Clinical Hypertension</i> , 2019, 21, 1654-1663.	2.0	8
151	Prevalence of Metabolic Syndrome and Its Determinants in Newly-Diagnosed Adult-Onset Diabetes in China: A Multi-Center, Cross-Sectional Survey. <i>Frontiers in Endocrinology</i> , 2019, 10, 661.	3.5	26
152	Characteristics of Newly Diagnosed Type 2 Diabetes in Chinese Older Adults: A National Prospective Cohort Study. <i>Journal of Diabetes Research</i> , 2019, 2019, 1-9.	2.3	7
153	Comparison between newly diagnosed hypertension in diabetes and newly diagnosed diabetes in hypertension. <i>Diabetology and Metabolic Syndrome</i> , 2019, 11, 69.	2.7	6
154	Clinical Implications of Urinary C-Peptide Creatinine Ratio in Patients with Different Types of Diabetes. <i>Journal of Diabetes Research</i> , 2019, 2019, 1-8.	2.3	4
155	Prevalence and identification of type 1 diabetes in Chinese adults with newly diagnosed diabetes. <i>Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy</i> , 2019, Volume 12, 1527-1541.	2.4	23
156	Cost-effectiveness analysis of dapagliflozin treatment versus metformin treatment in Chinese population with type 2 diabetes. <i>Journal of Medical Economics</i> , 2019, 22, 336-343.	2.1	19
157	The risk factors of glycemic control, blood pressure control, lipid control in Chinese patients with newly diagnosed type 2 diabetes _ A nationwide prospective cohort study. <i>Scientific Reports</i> , 2019, 9, 7709.	3.3	19
158	Type 2 diabetes treatment and outcomes worldwide: A short review of the DISCOVER study programme. <i>Diabetes, Obesity and Metabolism</i> , 2019, 21, 2349-2353.	4.4	12
159	Study Protocol for a Prospective, Multicenter, Randomized, Open-Label, Parallel-Group Clinical Trial Comparing the Efficacy and Safety of a Needle-Free Insulin Injector and a Conventional Insulin Pen in Controlling Blood Glucose Concentrations in Chinese Patients with Type 2 Diabetes Mellitus (The TJ ETQq1 1 0.784314 rgBT ³ /Overlo	2.9	3
160	Prevalence of thyroid dysfunction in older Chinese patients with type 2 diabetes – A multicenter cross-sectional observational study across China. <i>PLoS ONE</i> , 2019, 14, e0216151.	2.5	16
161	Independent markers of nonalcoholic fatty liver disease in a gentrifying population-based Chinese cohort. <i>Diabetes/Metabolism Research and Reviews</i> , 2019, 35, e3156.	4.0	25
162	Standards of medical care for type 2 diabetes in China 2019. <i>Diabetes/Metabolism Research and Reviews</i> , 2019, 35, e3158.	4.0	404

#	ARTICLE	IF	CITATIONS
163	Chinese clinical guidelines for continuous glucose monitoring (2018 edition). <i>Diabetes/Metabolism Research and Reviews</i> , 2019, 35, e3152.	4.0	9
164	Safety and efficacy of ertugliflozin in Asian patients with type 2 diabetes mellitus inadequately controlled with metformin monotherapy: VERTIS Asia. <i>Diabetes, Obesity and Metabolism</i> , 2019, 21, 1474-1482.	4.4	38
165	Association between serum thyrotropin within the euthyroid range and obesity. <i>Endocrine Journal</i> , 2019, 66, 451-457.	1.6	13
166	Treatment of type 2 diabetes mellitus worldwide: Baseline patient characteristics in the global DISCOVER study. <i>Diabetes Research and Clinical Practice</i> , 2019, 151, 20-32.	2.8	63
167	Eligibility of patients with type 2 diabetes for sodium-glucose cotransporter 2 inhibitor cardiovascular outcomes trials: a global perspective from the DISCOVER study. <i>BMJ Open Diabetes Research and Care</i> , 2019, 7, e000627.	2.8	14
168	Effect of incretin-based therapies on cancers of digestive system among 101 595 patients with type 2 diabetes mellitus: a systematic review and network meta-analysis combining 84 trials with a median duration of 30 weeks. <i>BMJ Open Diabetes Research and Care</i> , 2019, 7, e000728.	2.8	10
169	Neurological Manifestation of Incretin-Based Therapies in Patients with Type 2 Diabetes: A Systematic Review and Network Meta-Analysis. , 2019, 10, 1311.		4
170	A Decision-Support Software to Improve the Standard Care in Chinese Type 2 Diabetes. <i>Journal of Diabetes Research</i> , 2019, 2019, 1-6.	2.3	3
171	<p>Urinary C-Peptide Creatinine Ratio as a Non-Invasive Tool for Identifying Latent Autoimmune Diabetes in Adults (LADA)</p>. <i>Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy</i> , 2019, Volume 12, 2531-2537.	2.4	7
172	Novel subgroups of patients with adult-onset diabetes in Chinese and US populations. <i>Lancet Diabetes and Endocrinology</i> , 2019, 7, 9-11.	11.4	138
173	Associations of Bone Mineral Density and Bone Metabolism Indices with Urine Albumin to Creatinine Ratio in Chinese Patients with Type 2 Diabetes. <i>Experimental and Clinical Endocrinology and Diabetes</i> , 2019, 6, 50-55.	1.2	11
174	Assessing the Burden of Type 2 Diabetes in China Considering the Current Status-Quo Management and Implications of Improved Management Using a Modeling Approach. <i>Value in Health Regional Issues</i> , 2019, 18, 36-46.	1.2	14
175	Identification of autoimmune type 1 diabetes and multiple organ-specific autoantibodies in adult-onset non-insulin-requiring diabetes in China: A population-based multicentre nationwide survey. <i>Diabetes, Obesity and Metabolism</i> , 2019, 21, 893-902.	4.4	24
176	Associations between metformin use and vitamin B ₁₂ levels, anemia, and neuropathy in patients with diabetes: a meta-analysis. <i>Journal of Diabetes</i> , 2019, 11, 729-743.	1.8	61
177	A new clinical screening strategy and prevalence estimation for glucokinase variant-induced diabetes in an adult Chinese population. <i>Genetics in Medicine</i> , 2019, 21, 939-947.	2.4	25
178	The effect of diabetes self-management education on psychological status and blood glucose in newly diagnosed patients with diabetes type 2. <i>Patient Education and Counseling</i> , 2018, 101, 1427-1432.	2.2	40
179	Characteristics and Ongoing Autoimmunity of Patients With Long-standing Type 1 Diabetes Living in China. <i>Diabetes Care</i> , 2018, 41, e97-e98.	8.6	7
180	Clinical characteristics of type 2 diabetes patients with discordance between <sc>HbA _{1c} </sc> and fasting plasma glucose in the real world: <sc>A</sc>n analysis of the <sc>ORBIT</sc> study. <i>Diabetes/Metabolism Research and Reviews</i> , 2018, 34, e2977.	4.0	2

#	ARTICLE	IF	CITATIONS
181	Incidence of type 1 diabetes in China, 2010-13: population based study. <i>BMJ: British Medical Journal</i> , 2018, 360, j5295.	2.3	193
182	Dorzagliatin monotherapy in Chinese patients with type 2 diabetes: a dose-ranging, randomised, double-blind, placebo-controlled, phase 2 study. <i>Lancet Diabetes and Endocrinology</i> , 2018, 6, 627-636.	11.4	61
183	Elevated serum ferritin concentration is associated with incident type 2 diabetes mellitus in a Chinese population: A prospective cohort study. <i>Diabetes Research and Clinical Practice</i> , 2018, 139, 155-162.	2.8	24
184	Prevalence of and risk factors for diabetic ketosis in Chinese diabetic patients with random blood glucose levels >13.9 mmol/L: Results from the CHina study in prEvalence of diabetiC Ketosis (CHECK) study. <i>Journal of Diabetes</i> , 2018, 10, 249-255.	1.8	6
185	Meta-analysis and critical review on the efficacy and safety of alpha-glucosidase inhibitors in Asian and non-Asian populations. <i>Journal of Diabetes Investigation</i> , 2018, 9, 321-331.	2.4	43
186	Addition of dipeptidyl peptidase-4 inhibitors to insulin treatment in type 2 diabetes patients: A meta-analysis. <i>Journal of Diabetes Investigation</i> , 2018, 9, 813-821.	2.4	19
187	Long exposure to type 2 diabetes and risk of non-fatal coronary heart disease in Chinese females and males: Findings from a China national cross-sectional study. <i>Diabetes Research and Clinical Practice</i> , 2018, 137, 119-127.	2.8	1
188	No disparity of the efficacy and all-cause mortality between Asian and non-Asian type 2 diabetes patients with sodium-glucose cotransporter 2 inhibitors treatment: A meta-analysis. <i>Journal of Diabetes Investigation</i> , 2018, 9, 850-861.	2.4	49
189	Epidemiological characteristics of lower extremity arterial disease in Chinese diabetes patients at high risk: a prospective, multicenter, cross-sectional study. <i>Journal of Diabetes and Its Complications</i> , 2018, 32, 150-156.	2.3	30
190	The Association Between the Dosage of SGLT2 Inhibitor and Weight Reduction in Type 2 Diabetes Patients: A Meta-Analysis. <i>Obesity</i> , 2018, 26, 70-80.	3.0	109
191	Comparative effectiveness of metformin monotherapy in extended release and immediate release formulations for the treatment of type 2 diabetes in treatment-naïve Chinese patients: Analysis of results from the CONSENT trial. <i>Diabetes, Obesity and Metabolism</i> , 2018, 20, 1006-1013.	4.4	14
192	Saxagliptin add-on therapy in Chinese patients with type 2 diabetes inadequately controlled by insulin with or without metformin: Results from the SUPER study, a randomized, double-blind, placebo-controlled trial. <i>Diabetes, Obesity and Metabolism</i> , 2018, 20, 1044-1049.	4.4	9
193	Low triglyceride as a marker for increased risk of cardiovascular diseases in patients with long-term type 2 diabetes: A cross-sectional survey in China. <i>Diabetes/Metabolism Research and Reviews</i> , 2018, 34, e2960.	4.0	11
194	Patterns of glycaemic control in patients with type 2 diabetes mellitus initiating second-line therapy after metformin monotherapy: retrospective data for 10%256 individuals from the United Kingdom and Germany. <i>Diabetes, Obesity and Metabolism</i> , 2018, 20, 389-399.	4.4	38
195	A Screening Approach for Mitochondrial tRNA ^{Leu} (UUR) A3243G Mutation in a Hospital-Based Population with Diabetes. <i>Chinese Medical Journal</i> , 2018, 131, 1117-1119.	2.3	1
196	Comparison of Placebo Effect between Asian and Caucasian Type 2 Diabetic Patients. <i>Chinese Medical Journal</i> , 2018, 131, 1605-1612.	2.3	3
197	Predictors of Glycemic Control in Patients with Type 2 Diabetes: A Subgroup Analysis of the Observational Registry of Basal Insulin Treatment Study in China. <i>Diabetes Technology and Therapeutics</i> , 2018, 20, 825-832.	4.4	1
198	Epidemic T2DM, early development and epigenetics: implications of the Chinese Famine. <i>Nature Reviews Endocrinology</i> , 2018, 14, 738-746.	9.6	100

#	ARTICLE	IF	CITATIONS
199	Comparison of the Effect of Glycemic Control in Type 2 Diabetes Outpatients Treated With Premixed and Basal Insulin Monotherapy in China. <i>Frontiers in Endocrinology</i> , 2018, 9, 639.	3.5	8
200	Insulin Injection Technique in China Compared with the Rest of the World. <i>Diabetes Therapy</i> , 2018, 9, 2357-2368.	2.5	9
201	Regional Differences in the Prevalence of Coronary Heart Disease and Stroke in Patients With Type 2 Diabetes in China. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2018, 103, 3319-3330.	3.6	24
202	Interactive effect of serum uric acid and total bilirubin for micro-vascular disease of type 2 diabetes in China. <i>Journal of Diabetes and Its Complications</i> , 2018, 32, 1000-1005.	2.3	15
203	Efficacy and Safety of Initial Combination Therapy in Treatment-Naïve Type 2 Diabetes Patients: A Systematic Review and Meta-analysis. <i>Diabetes Therapy</i> , 2018, 9, 1995-2014.	2.5	28
204	Lower Circulating miR-122 Level in Patients with HNF1A Variant-Induced Diabetes Compared with Type 2 Diabetes. <i>Journal of Diabetes Research</i> , 2018, 2018, 1-6.	2.3	11
205	Association between physical activity and abnormal glucose metabolism—A population-based cross-sectional study in China. <i>Journal of Diabetes and Its Complications</i> , 2018, 32, 746-752.	2.3	11
206	The global impact of the International Federation of Clinical Chemistry and Laboratory Medicine, Education and Management Division: engaging stakeholders and assessing HbA _{1c} quality in a multicentre study across China. <i>Clinical Chemistry and Laboratory Medicine</i> , 2018, 57, 288-295.	2.3	2
207	Gender Difference in the Association of Early- vs. Late-Onset Type 2 Diabetes with Non-Fatal Microvascular Disease in China: A Cross-sectional Study. <i>Frontiers in Endocrinology</i> , 2018, 9, 15.	3.5	5
208	The association between insurance coverage for insulin pen needles and healthcare resource utilization among insulin-dependent patients with diabetes in China. <i>BMC Health Services Research</i> , 2018, 18, 300.	2.2	7
209	Blood glucose profiles in East Asian and Caucasian injection-naïve patients with type 2 diabetes inadequately controlled on oral medication: a pooled analysis. <i>Diabetes/Metabolism Research and Reviews</i> , 2018, 34, e3062.	4.0	11
210	Disparities in the Efficacy of Metformin in Combination with Dipeptidyl Peptidase-4 Inhibitor as Initial Treatment Stratified by Dosage and Ethnicity: A Meta-Analysis. <i>Diabetes Technology and Therapeutics</i> , 2018, 20, 704-714.	4.4	2
211	The association of smoking and risk of diabetic retinopathy in patients with type 1 and type 2 diabetes: a meta-analysis. <i>Endocrine</i> , 2018, 62, 299-306.	2.3	65
212	Safety and Efficacy of High Versus Standard Starting Doses of Insulin Glargine in Overweight and Obese Chinese Individuals with Type 2 Diabetes Mellitus Inadequately Controlled on Oral Antidiabetic Medications (Beyond VII): Study Protocol for a Randomized Controlled Trial. <i>Advances in Therapy</i> , 2018, 35, 864-874.	2.9	5
213	Prevalence, treatment patterns and control rates of metabolic syndrome in a Chinese diabetic population: China Cardiometabolic Registries 3B study. <i>Journal of Diabetes Investigation</i> , 2018, 9, 789-798.	2.4	15
214	A pituitary abscess with one year follow-up after conservative treatment: A case report. <i>Neuroendocrinology Letters</i> , 2018, 38, 532-536.	0.2	0
215	Structured self-monitoring of blood glucose regimens improve glycemic control in poorly controlled Chinese patients on insulin therapy: Results from COMPASS. <i>Journal of Diabetes</i> , 2017, 9, 495-501.	1.8	12
216	Lipohypertrophy in China: Prevalence, Risk Factors, Insulin Consumption, and Clinical Impact. <i>Diabetes Technology and Therapeutics</i> , 2017, 19, 61-67.	4.4	61

#	ARTICLE	IF	CITATIONS
217	Effects of Acarbose on the Gut Microbiota of Prediabetic Patients: A Randomized, Double-blind, Controlled Crossover Trial. <i>Diabetes Therapy</i> , 2017, 8, 293-307.	2.5	128
218	Efficacy and safety of fixed-dose combination therapy, alogliptin plus metformin, in Asian patients with type 2 diabetes: A phase 3 trial. <i>Diabetes, Obesity and Metabolism</i> , 2017, 19, 754-758.	4.4	16
219	Observational registry of basal insulin treatment (ORBIT) in patients with type 2 diabetes uncontrolled with oral antihyperglycaemic drugs: real-life use of basal insulin in China. <i>Diabetes, Obesity and Metabolism</i> , 2017, 19, 822-830.	4.4	45
220	Comparisons of weight changes between sodium-glucose cotransporter 2 inhibitors treatment and glucagon-like peptide-1 analogs treatment in type 2 diabetes patients: A meta-analysis. <i>Journal of Diabetes Investigation</i> , 2017, 8, 510-517.	2.4	51
221	Longitudinal association between fasting blood glucose concentrations and first stroke in hypertensive adults in China: effect of folic acid intervention. <i>American Journal of Clinical Nutrition</i> , 2017, 105, 564-570.	4.7	21
222	Efficacy and safety of metformin and sitagliptin based triple antihyperglycemic therapy (STRATEGY): a multicenter, randomized, controlled, non-inferiority clinical trial. <i>Science China Life Sciences</i> , 2017, 60, 225-238.	4.9	20
223	Factors of primary and secondary sulfonylurea failure in type 2 diabetic subjects. <i>Journal of Diabetes</i> , 2017, 9, 1091-1099.	1.8	4
224	Comparative effectiveness and safety of different basal insulins in a real-world setting. <i>Diabetes, Obesity and Metabolism</i> , 2017, 19, 1116-1126.	4.4	11
225	Type 1 diabetes mellitus care and education in China: The 3C study of coverage, cost, and care in Beijing and Shantou. <i>Diabetes Research and Clinical Practice</i> , 2017, 129, 32-42.	2.8	27
226	The characteristics of newly diagnosed adult early-onset diabetes: a population-based cross-sectional study. <i>Scientific Reports</i> , 2017, 7, 46534.	3.3	34
227	Influence of the SLC1B3 Gene on Sulfonylurea Failure in Patients with Type 2 Diabetes in China. <i>Experimental and Clinical Endocrinology and Diabetes</i> , 2017, 125, 449-453.	1.2	4
228	Gaps and barriers in the control of blood glucose in people with type 2 diabetes. <i>Diabetes and Vascular Disease Research</i> , 2017, 14, 172-183.	2.0	102
229	Towards an improved global understanding of treatment and outcomes in people with type 2 diabetes: Rationale and methods of the DISCOVER observational study program. <i>Journal of Diabetes and Its Complications</i> , 2017, 31, 1188-1196.	2.3	46
230	Urine Proteome Specific for Eye Damage Can Predict Kidney Damage in Patients With Type 2 Diabetes: A Case-Control and a 5.3-Year Prospective Cohort Study. <i>Diabetes Care</i> , 2017, 40, 253-260.	8.6	32
231	The serum protein responses to treatment with Xiaohe Pill and Glibenclamide in type 2 diabetes patients. <i>Clinical Proteomics</i> , 2017, 14, 19.	2.1	8
232	Role of Continuous Glucose Monitoring in Clinical Trials: Recommendations on Reporting. <i>Diabetes Technology and Therapeutics</i> , 2017, 19, 391-399.	4.4	45
233	Relationship between healthy lifestyle behaviors and cardiovascular risk factors in Chinese patients with type 2 diabetes mellitus: a subanalysis of the CCMR-3B STUDY. <i>Acta Diabetologica</i> , 2017, 54, 569-579.	2.5	14
234	Efficacy and safety of premixed insulin analogs in Asian patients with type 2 diabetes: A systematic review. <i>Journal of Diabetes Investigation</i> , 2017, 8, 518-534.	2.4	17

#	ARTICLE	IF	CITATIONS
235	Relationship Between Gestational Weight Gain and Pregnancy Complications or Delivery Outcome. <i>Scientific Reports</i> , 2017, 7, 12531.	3.3	38
236	Comparison between insulin degludec/liraglutide treatment and insulin glargine/lixisenatide treatment in type 2 diabetes: a systematic review and meta-analysis. <i>Expert Opinion on Pharmacotherapy</i> , 2017, 18, 1789-1798.	1.8	26
237	Observational Registry of Basal Insulin Treatment in Patients with Type 2 Diabetes in China: Safety and Hypoglycemia Predictors. <i>Diabetes Technology and Therapeutics</i> , 2017, 19, 675-684.	4.4	7
238	Gender Disparities in Lipid Goal Attainment among Type 2 Diabetes Outpatients with Coronary Heart Disease: Results from the CCMR-3B Study. <i>Scientific Reports</i> , 2017, 7, 12648.	3.3	12
239	Gastrointestinal Adverse Events of Dipeptidyl Peptidase 4 Inhibitors in Type 2 Diabetes: A Systematic Review and Network Meta-analysis. <i>Clinical Therapeutics</i> , 2017, 39, 1780-1789.e33.	2.5	33
240	Pharmacokinetics and Preliminary Pharmacodynamics of Single- and Multiple-dose Lyophilized Recombinant Glucagon-like Peptide-1 Receptor Agonist (rE-4) in Chinese Patients with Type 2 Diabetes Mellitus. <i>Clinical Drug Investigation</i> , 2017, 37, 1107-1115.	2.2	2
241	A Multicenter Evaluation of the Performance and Usability of a Novel Glucose Monitoring System in Chinese Adults With Diabetes. <i>Journal of Diabetes Science and Technology</i> , 2017, 11, 290-295.	2.2	51
242	Association of serum ferritin levels with metabolic syndrome and insulin resistance in a Chinese population. <i>Journal of Diabetes and Its Complications</i> , 2017, 31, 364-368.	2.3	35
243	Efficacy and safety of dapagliflozin in Asian patients: A pooled analysis. <i>Journal of Diabetes</i> , 2017, 9, 787-799.	1.8	16
244	Clinical and Genetic Features of Patients With Type 2 Diabetes and Renal Glycosuria. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2017, 102, 1548-1556.	3.6	22
245	A Novel Mutation of PRKAR1A Caused Carney Complex in a Chinese Patient. <i>Chinese Medical Journal</i> , 2017, 130, 3009-3010.	2.3	1
246	Molecular Mechanisms and Treatment Strategies in Diabetic Nephropathy: New Avenues for Calcium Dobesilateâ€”Free Radical Scavenger and Growth Factor Inhibition. <i>BioMed Research International</i> , 2017, 2017, 1-11.	1.9	32
247	Associated Factors with Biochemical Hypoglycemia during an Oral Glucose Tolerance Test in a Chinese Population. <i>Journal of Diabetes Research</i> , 2017, 2017, 1-5.	2.3	5
248	Rationale, Design, and Baseline Characteristics of Beijing Prediabetes Reversion Program: A Randomized Controlled Clinical Trial to Evaluate the Efficacy of Lifestyle Intervention and/or Pioglitazone in Reversion to Normal Glucose Tolerance in Prediabetes. <i>Journal of Diabetes Research</i> , 2017, 2017, 1-11.	2.3	12
249	The Magnitude of Weight Loss Induced by Metformin is Independently Associated with BMI at Baseline in Newly Diagnosed Type 2 Diabetes: Post-hoc Analysis from Data of a Phase IV Open-labeled Trial. <i>Advances in Clinical and Experimental Medicine</i> , 2017, 26, 671-677.	1.4	4
250	Comparison of efficacy and safety of two starting insulin regimens in non-Asian, Asian Indian, and East Asian patients with type 2 diabetes: a post hoc analysis of the PARADIGM study. <i>Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy</i> , 2016, Volume 9, 243-249.	2.4	17
251	The Association of Retinopathy and Plasma Glucose and HbA1c: A Validation of Diabetes Diagnostic Criteria in a Chinese Population. <i>Journal of Diabetes Research</i> , 2016, 2016, 1-7.	2.3	16
252	Diabetes awareness, treatment, control rates and associated risk factors among Beijing residents in 2011: A cross-sectional survey. <i>Chronic Diseases and Translational Medicine</i> , 2016, 2, 147-158.	1.2	9

#	ARTICLE	IF	CITATIONS
253	DPP-4 Inhibitor Treatment in Chinese Type 2 Diabetes Patients: A Meta-Analysis. <i>Diabetes Technology and Therapeutics</i> , 2016, 18, 784-793.	4.4	14
254	Metabolic Surgery in the Treatment Algorithm for Type 2 Diabetes: A Joint Statement by International Diabetes Organizations. <i>Diabetes Care</i> , 2016, 39, 861-877.	8.6	718
255	Brain derived neurotrophic factor in newly diagnosed diabetes and prediabetes. <i>Molecular and Cellular Endocrinology</i> , 2016, 429, 106-113.	3.2	31
256	Decreased Glycemic Difference Between Diabetes and Nondiabetes in the Elderly Leads to the Reduced Diagnostic Accuracy of Hemoglobin A1c for Diabetes Screening in an Aged Chinese Population. <i>Diabetes Technology and Therapeutics</i> , 2016, 18, 226-232.	4.4	12
257	Effectiveness of clinical alternatives to nerve conduction studies for screening for diabetic distal symmetrical polyneuropathy: A multi-center study. <i>Diabetes Research and Clinical Practice</i> , 2016, 115, 150-156.	2.8	6
258	Association of Diabetic Microvascular Complications and Parameters of Obstructive Sleep Apnea in Patients with Type 2 Diabetes. <i>Diabetes Technology and Therapeutics</i> , 2016, 18, 415-420.	4.4	35
259	New Insulin Delivery Recommendations. <i>Mayo Clinic Proceedings</i> , 2016, 91, 1231-1255.	3.0	200
260	Predictors of Renal Function Decline in Chinese Patients with Type 2 Diabetes Mellitus and in a Subgroup of Normoalbuminuria: A Retrospective Cohort Study. <i>Diabetes Technology and Therapeutics</i> , 2016, 18, 635-643.	4.4	5
261	Standards of care for type 2 diabetes in China. <i>Diabetes/Metabolism Research and Reviews</i> , 2016, 32, 442-458.	4.0	236
262	DPP-4 inhibitors and risk of infections: a meta-analysis of randomized controlled trials. <i>Diabetes/Metabolism Research and Reviews</i> , 2016, 32, 391-404.	4.0	54
263	Uric acid, renal function and risk of hypoglycaemia in Chinese type 2 diabetes patients. <i>Diabetes/Metabolism Research and Reviews</i> , 2016, 32, 875-882.	4.0	6
264	Randomized clinical trial of the safety and efficacy of sitagliptin and metformin co-administered to Chinese patients with type 2 diabetes mellitus. <i>Journal of Diabetes Investigation</i> , 2016, 7, 727-736.	2.4	23
265	Glycated albumin is superior to glycated hemoglobin for glycemic control assessment at an early stage of diabetes treatment: A multicenter, prospective study. <i>Journal of Diabetes and Its Complications</i> , 2016, 30, 1609-1613.	2.3	21
266	Genetic and Clinical Predictive Factors of Sulfonylurea Failure in Patients with Type 2 Diabetes. <i>Diabetes Technology and Therapeutics</i> , 2016, 18, 586-593.	4.4	8
267	Interactive effect of serum uric acid and total bilirubin for cardiovascular disease in Chinese patients with type 2 diabetes. <i>Scientific Reports</i> , 2016, 6, 36437.	3.3	15
268	Management of hypertension and diabetes mellitus by cardiovascular and endocrine physicians. <i>Journal of Hypertension</i> , 2016, 34, 1648-1653.	0.5	23
269	Association between socioeconomic status and metabolic control and diabetes complications: a cross-sectional nationwide study in Chinese adults with type 2 diabetes mellitus. <i>Cardiovascular Diabetology</i> , 2016, 15, 61.	6.8	56
270	Efficacy of hypoglycemic treatment in type 2 diabetes stratified by age or diagnosed age: a meta-analysis. <i>Expert Opinion on Pharmacotherapy</i> , 2016, 17, 1591-1598.	1.8	2

#	ARTICLE	IF	CITATIONS
271	HDL in diabetic nephropathy has less effect in endothelial repairing than diabetes without complications. <i>Lipids in Health and Disease</i> , 2016, 15, 76.	3.0	12
272	Effects of body mass index or dosage on gastrointestinal disorders associated with extended-release metformin in type 2 diabetes: Sub-analysis of a Phase IV open-label trial in Chinese patients. <i>Diabetes and Metabolic Syndrome: Clinical Research and Reviews</i> , 2016, 10, 137-142.	3.6	9
273	Non-linear associations of risk factors with mild hypoglycemia among Chinese patients with type 2 diabetes. <i>Journal of Diabetes and Its Complications</i> , 2016, 30, 462-468.	2.3	8
274	Plasma NT-proBNP is independently associated with albuminuria in type 2 diabetes. <i>Journal of Diabetes and Its Complications</i> , 2016, 30, 669-674.	2.3	5
275	Risk of non-fatal cardiovascular diseases in early-onset versus late-onset type 2 diabetes in China: a cross-sectional study. <i>Lancet Diabetes and Endocrinology</i> , 2016, 4, 115-124.	11.4	173
276	Prevalence of Obesity and Its Influence on Achievement of Cardiometabolic Therapeutic Goals in Chinese Type 2 Diabetes Patients: An Analysis of the Nationwide, Cross-Sectional 3B Study. <i>PLoS ONE</i> , 2016, 11, e0144179.	2.5	31
277	Cigarette Smoking Is Associated with a Lower Prevalence of Newly Diagnosed Diabetes Screened by OGTT than Non-Smoking in Chinese Men with Normal Weight. <i>PLoS ONE</i> , 2016, 11, e0149234.	2.5	15
278	Efficacy and Acceptability of Glycemic Control of Glucagon-Like Peptide-1 Receptor Agonists among Type 2 Diabetes: A Systematic Review and Network Meta-Analysis. <i>PLoS ONE</i> , 2016, 11, e0154206.	2.5	22
279	Clinical Characteristics of Young Type 2 Diabetes Patients with Atherosclerosis. <i>PLoS ONE</i> , 2016, 11, e0159055.	2.5	12
280	Baseline Body Mass Index and the Efficacy of Hypoglycemic Treatment in Type 2 Diabetes: A Meta-Analysis. <i>PLoS ONE</i> , 2016, 11, e0166625.	2.5	21
281	Short-term intensive insulin therapy at diagnosis in type 2 diabetes: plan for filling the gaps. <i>Diabetes/Metabolism Research and Reviews</i> , 2015, 31, 537-544.	4.0	16
282	National Variations in Comorbidities, Glycosylated Hemoglobin Reduction, and Insulin Dosage in Asian Patients with Type 2 Diabetes: The FINE-Asia Registry. <i>Diabetes Therapy</i> , 2015, 6, 519-530.	2.5	15
283	Status of basal-supported oral therapy in Chinese type 2 diabetic patients with inadequate glycemic control on oral anti-diabetic drugs. <i>Diabetes/Metabolism Research and Reviews</i> , 2015, 31, 796-802.	4.0	1
284	Relationship Between Serum Zinc Level and Microvascular Complications in Patients with Type 2 Diabetes. <i>Chinese Medical Journal</i> , 2015, 128, 3276-3282.	2.3	37
285	Hypoglycaemia, Abnormal Lipids, and Cardiovascular Disease among Chinese with Type 2 Diabetes. <i>BioMed Research International</i> , 2015, 2015, 1-8.	1.9	5
286	Effects of Glucagon-Like Peptide-1 Receptor Agonists on Weight Loss in Patients with Type 2 Diabetes: A Systematic Review and Network Meta-Analysis. <i>Journal of Diabetes Research</i> , 2015, 2015, 1-9.	2.3	87
287	Gastrointestinal Adverse Events of Glucagon-Like Peptide-1 Receptor Agonists in Patients with Type 2 Diabetes: A Systematic Review and Network Meta-Analysis. <i>Diabetes Technology and Therapeutics</i> , 2015, 17, 35-42.	4.4	99
288	Prevalence of microvascular diseases among tertiary care Chinese with early versus late onset of type 2 diabetes. <i>Journal of Diabetes and Its Complications</i> , 2015, 29, 32-37.	2.3	40

#	ARTICLE	IF	CITATIONS
289	Effect of Glucagon-like Peptide-1 Receptor Agonists on Lipid Profiles Among Type 2 Diabetes: A Systematic Review and Network Meta-analysis. <i>Clinical Therapeutics</i> , 2015, 37, 225-241.e8.	2.5	155
290	Type 1 diabetes stigma in China: A call to end the devaluation of individuals living with a manageable chronic disease. <i>Diabetes Research and Clinical Practice</i> , 2015, 107, 306-307.	2.8	32
291	Determinants of poor glycemic control in Chinese men with type 2 diabetes: a cross-sectional survey of 15,427 men in 77 tertiary hospitals in China. <i>International Journal of Diabetes in Developing Countries</i> , 2015, 35, 488-492.	0.8	2
292	Increasing body mass index identifies Chinese patients with type 2 diabetes mellitus at risk of poor outcomes. <i>Journal of Diabetes and Its Complications</i> , 2015, 29, 488-496.	2.3	3
293	Efficacy and Safety of Linagliptin Co-Administered with Low-Dose Metformin Once Daily Versus High-Dose Metformin Twice Daily in Treatment-Naïve Patients with Type 2 Diabetes: a Double-Blind Randomized Trial. <i>Advances in Therapy</i> , 2015, 32, 201-215.	2.9	15
294	Investigation of 2 Models to Set and Evaluate Quality Targets for Hb A1c: Biological Variation and Sigma-Metrics. <i>Clinical Chemistry</i> , 2015, 61, 752-759.	3.2	69
295	Dietary patterns associated with HbA1c and LDL cholesterol among individuals with type 1 diabetes in China. <i>Journal of Diabetes and Its Complications</i> , 2015, 29, 343-349.	2.3	29
296	<i>IL-1B</i> rs1143623 and <i>EEF1A1P11-RPL7P9</i> rs10783050 polymorphisms affect the glucose-lowering efficacy of metformin in Chinese overweight or obese Type 2 diabetes mellitus patients. <i>Pharmacogenomics</i> , 2015, 16, 1621-1629.	1.3	6
297	Treatment Patterns and Glycemic Control in Older Adults with Type 2 Diabetes Mellitus Receiving Only Oral Antidiabetes Drugs in China. <i>Diabetes Technology and Therapeutics</i> , 2015, 17, 816-824.	4.4	14
298	Observational Registry of Basal Insulin Treatment (ORBIT) in Patients with Type 2 Diabetes Uncontrolled by Oral Hypoglycemic Agents in China—Study Design and Baseline Characteristics. <i>Diabetes Technology and Therapeutics</i> , 2015, 17, 735-744.	4.4	33
299	Comparisons of the efficacy of glucose control, lipid profile, and β -cell function between DPP-4 inhibitors and AGI treatment in type 2 diabetes patients: a meta-analysis. <i>Endocrine</i> , 2015, 50, 590-597.	2.3	19
300	Impact of GLP-1 receptor agonists on blood pressure, heart rate and hypertension among patients with type 2 diabetes: A systematic review and network meta-analysis. <i>Diabetes Research and Clinical Practice</i> , 2015, 110, 26-37.	2.8	216
301	Clinical Utility of SMBG: Recommendations on the Use and Reporting of SMBG in Clinical Research. <i>Diabetes Care</i> , 2015, 38, 1627-1633.	8.6	28
302	Depression in Chinese patients with type 2 diabetes: associations with hyperglycemia, hypoglycemia, and poor treatment adherence. <i>Journal of Diabetes</i> , 2015, 7, 800-808.	1.8	81
303	China type 2 diabetes treatment status survey of treatment pattern of oral drugs users. <i>Journal of Diabetes</i> , 2015, 7, 166-173.	1.8	39
304	Glycemic Control Rate of T2DM Outpatients in China: A Multi-Center Survey. <i>Medical Science Monitor</i> , 2015, 21, 1440-1446.	1.1	41
305	ACEI/ARB Underused in Patients with Type 2 Diabetes in Chinese Population (CCMR-3B Study). <i>PLoS ONE</i> , 2015, 10, e0116970.	2.5	8
306	Association between Family History Risk Categories and Prevalence of Diabetes in Chinese Population. <i>PLoS ONE</i> , 2015, 10, e0117044.	2.5	31

#	ARTICLE	IF	CITATIONS
307	Efficacy and Safety of Avandamet or Uptitrated Metformin Treatment in Patients with Type 2 Diabetes Inadequately Controlled with Metformin Alone. <i>Chinese Medical Journal</i> , 2015, 128, 1279-1287.	2.3	3
308	Comparison of the dietary intakes of individuals with and without type 1 diabetes in China. <i>Asia Pacific Journal of Clinical Nutrition</i> , 2015, 24, 639-49.	0.4	7
309	Obesity-Related Genomic Loci Are Associated with Type 2 Diabetes in a Han Chinese Population. <i>PLoS ONE</i> , 2014, 9, e104486.	2.5	25
310	Non-pharmaceutical factors for poor glycemic control in 13,970 Chinese women with drug-treated type 2 diabetes: a cross-sectional survey in 77 tertiary hospitals in four Chinese cities. <i>Patient Preference and Adherence</i> , 2014, 8, 1161.	1.8	6
311	P38 Plays an Important Role in Glucolipototoxicity-Induced Apoptosis in INS-1 Cells. <i>Journal of Diabetes Research</i> , 2014, 2014, 1-7.	2.3	10
312	Analysis of the Associations between Vitamin D and Albuminuria or β -Cell Function in Chinese Type 2 Diabetes. <i>BioMed Research International</i> , 2014, 2014, 1-5.	1.9	10
313	Metabolic profiles and treatment gaps in young-onset type 2 diabetes in Asia (the JADE programme): a cross-sectional study of a prospective cohort. <i>Lancet Diabetes and Endocrinology</i> , 2014, 2, 935-943.	11.4	210
314	Albuminuria: Prevalence, associated risk factors and relationship with cardiovascular disease. <i>Journal of Diabetes Investigation</i> , 2014, 5, 464-471.	2.4	28
315	Hyperglycemia and duration of diabetes as risk factors for abnormal lipids: a cross sectional survey of 19,757 patients with type 2 diabetes in China. <i>Journal of Endocrinological Investigation</i> , 2014, 37, 843-852.	3.3	4
316	Hyperglycemia and Blood Pressure Treatment Goal: A Cross Sectional Survey of 18350 Patients with Type 2 Diabetes in 77 Tertiary Hospitals in China. <i>PLoS ONE</i> , 2014, 9, e103507.	2.5	2
317	BMI and waist circumference are associated with impaired glucose metabolism and type 2 diabetes in normal weight Chinese adults. <i>Journal of Diabetes and Its Complications</i> , 2014, 28, 470-476.	2.3	43
318	Silent myocardial ischemia detected by single photon emission computed tomography (SPECT) and risk of cardiac events among asymptomatic patients with type 2 diabetes: A meta-analysis of prospective studies. <i>Journal of Diabetes and Its Complications</i> , 2014, 28, 413-418.	2.3	14
319	Human serum acylcarnitine profiles in different glucose tolerance states. <i>Diabetes Research and Clinical Practice</i> , 2014, 104, 376-382.	2.8	35
320	Dapagliflozin as Monotherapy in Drug-Naive Asian Patients With Type 2 Diabetes Mellitus: A Randomized, Blinded, Prospective Phase III Study. <i>Clinical Therapeutics</i> , 2014, 36, 84-100.e9.	2.5	139
321	Sex disparity in the risk of diabetes-associated stroke. <i>Lancet</i> , 2014, 383, 1948-1950.	13.7	2
322	Age at Diagnosis and C-Peptide Level Are Associated with Diabetic Retinopathy in Chinese. <i>PLoS ONE</i> , 2014, 9, e91174.	2.5	20
323	Effectiveness of different waist circumference cut-off values in predicting metabolic syndrome prevalence and risk factors in adults in China. <i>Biomedical and Environmental Sciences</i> , 2014, 27, 325-34.	0.2	24
324	Understanding the standard of care in the treatment of type 2 diabetes in China: results from a national survey. <i>Chinese Medical Journal</i> , 2014, 127, 3524-9.	2.3	17

#	ARTICLE	IF	CITATIONS
325	Measuring depressive symptoms using the Patient Health Questionnaire-9 in Hong Kong Chinese subjects with type 2 diabetes. <i>Journal of Affective Disorders</i> , 2013, 151, 660-666.	4.1	54
326	Efficacy and safety of combination therapy with vildagliptin and metformin versus metformin up-titration in Chinese patients with type 2 diabetes mellitus: study design and rationale of the vision study. <i>Cardiovascular Diabetology</i> , 2013, 12, 118.	6.8	8
327	Glycemic control among patients in China with type 2 diabetes mellitus receiving oral drugs or injectables. <i>BMC Public Health</i> , 2013, 13, 602.	2.9	117
328	Primacy of the 3B Approach to Control Risk Factors for Cardiovascular Disease in Type 2 Diabetes Patients. <i>American Journal of Medicine</i> , 2013, 126, 925.e11-925.e22.	1.5	174
329	A Genome-Wide Association Study Identifies <i>GRK5</i> and <i>RASGRP1</i> as Type 2 Diabetes Loci in Chinese Hans. <i>Diabetes</i> , 2013, 62, 291-298.	0.6	166
330	Efficacy and safety of exenatide once-weekly vs exenatide twice-daily in Asian patients with type 2 diabetes mellitus. <i>Journal of Diabetes Investigation</i> , 2013, 4, 53-61.	2.4	72
331	Frequency, Immunogenetics, and Clinical Characteristics of Latent Autoimmune Diabetes in China (LADA China Study). <i>Diabetes</i> , 2013, 62, 543-550.	0.6	204
332	Efficacy and Safety of Traditional Chinese Medicine for Diabetes: A Double-Blind, Randomised, Controlled Trial. <i>PLoS ONE</i> , 2013, 8, e56703.	2.5	71
333	Impact of Baseline BMI on Glycemic Control and Weight Change with Metformin Monotherapy in Chinese Type 2 Diabetes Patients: Phase IV Open-Label Trial. <i>PLoS ONE</i> , 2013, 8, e57222.	2.5	30
334	Impact of Waist Circumference and Body Mass Index on Risk of Cardiometabolic Disorder and Cardiovascular Disease in Chinese Adults: A National Diabetes and Metabolic Disorders Survey. <i>PLoS ONE</i> , 2013, 8, e57319.	2.5	130
335	Comparisons of the Efficacy of Alpha Glucosidase Inhibitors on Type 2 Diabetes Patients between Asian and Caucasian. <i>PLoS ONE</i> , 2013, 8, e79421.	2.5	24
336	Impact of GLP-1 Receptor Agonists on Major Gastrointestinal Disorders for Type 2 Diabetes Mellitus: A Mixed Treatment Comparison Meta-Analysis. <i>Experimental Diabetes Research</i> , 2012, 2012, 1-14.	3.8	37
337	First insulinization with basal insulin in patients with Type 2 diabetes in a real-world setting in Asia. <i>Journal of Diabetes</i> , 2011, 3, 208-216.	1.8	53
338	Prevalence of Diabetes among Men and Women in China. <i>New England Journal of Medicine</i> , 2010, 362, 1090-1101.	27.0	2,685
339	662 A/G gene variation in human tumor necrosis factor receptor superfamily, member 9 (TNFRSF9). <i>Frontiers of Medicine in China</i> , 2008, 2, 283-285.	0.1	0
340	Simple tests to screen for diabetic peripheral neuropathy. <i>The Cochrane Library</i> , 0, , .	2.8	13
341	An Update on Animal Models of Osteogenesis Imperfecta. <i>Calcified Tissue International</i> , 0, , .	3.1	1